Santhera Pharmaceuticals Holding (SANN) AI Stock Analysis

• Market Cap: CHF154.00M
• Dividend Yield: N/A
• Average Volume (3M): 25.42K
• Price to Earnings (P/E): 2.6
• Beta (1Y): 0.27
• Revenue Growth: -62.17%
• EPS Growth: -166.33%
• Country: CH
• Employees: 78
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.74
• Shares Outstanding: 13,524,123
• 10 Day Avg. Volume: 30,163
• 30 Day Avg. Volume: 25,419
• PEG Ratio: 0.04
• Price to Book (P/B): -1.92
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF29.92
• Price Target Upside: 146.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 39 Underperform
• Price Target: CHF12.00 ▼(-0.99%Downside)

Santhera Pharmaceuticals' overall stock score is primarily impacted by its financial instability, including inconsistent revenue and negative profitability. Technical analysis corroborates a cautious outlook with mixed indicators, while unfavorable valuation metrics further weigh on the score.

Positive Factors

International Approvals

AGAMREE has received acceptance by Health Canada for the New Drug Submission with Priority Review, paving the way for it to become the first DMD drug approved in Canada.

Product Rollout

The European rollout of AGAMREE is accelerating, leading to an increase in the price target for Santhera Pharmaceuticals.

Reimbursement Agreement

The German reimbursement agreement for AGAMREE (vamorolone) makes it the first product to receive an agreed federal price in Germany for the treatment of Duchenne muscular dystrophy.

Negative Factors

Market Uncertainty

Santhera continues to engage in pricing negotiations and reimbursement decisions across multiple key European territories, indicating steady progress and market uptake.

Revenue Forecasts

Investors should be aware that the €52K reimbursement level in Germany exceeds our original expectations for European reimbursement, which we had initially projected at only €40K per patient.

Santhera Pharmaceuticals Holding Business Overview & Revenue Model

Company Description

Santhera Pharmaceuticals Holding (SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of rare neuromuscular and pulmonary diseases. The company is committed to addressing unmet medical needs and improving the quality of life for patients with severe, debilitating conditions. Santhera's core product portfolio includes therapies for Duchenne muscular dystrophy (DMD) and other rare diseases that have limited or no existing treatment options.

How the Company Makes Money

Santhera Pharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products. The company focuses on developing and marketing its proprietary drugs, particularly in the area of rare neuromuscular and pulmonary diseases. Revenue streams include product sales, which are driven by marketing and distribution agreements in various regions. Additionally, Santhera may engage in licensing agreements, collaborations, and partnerships with other pharmaceutical companies to co-develop and distribute its treatments, which can provide upfront payments, milestone payments, and royalties. These strategic partnerships and the successful launch of their key products are significant factors contributing to the company's earnings.

Santhera Pharmaceuticals Holding Financial Statement Overview

Summary

Santhera Pharmaceuticals faces significant financial challenges with volatile revenue, negative profitability, high leverage, and cash flow issues. Despite strong revenue growth in 2023, stability is questionable without operational and financial restructuring.

Income Statement

Santhera Pharmaceuticals has shown a volatile revenue trend with a significant drop in 2024 compared to 2023. The company struggles with profitability as indicated by negative EBIT and net income margins. However, past revenue growth was notable in 2023, suggesting potential for recovery if operational issues are addressed.

Balance Sheet

The company's balance sheet shows high leverage with a debt-to-equity ratio exceeding 1, indicating reliance on debt financing. The equity ratio is low, reflecting weak equity position. Persistent negative stockholders' equity in some years raises concerns about financial stability.

Cash Flow

Cash flow from operations has been negative in recent years, indicating challenges in generating cash internally. Positive financing cash flows highlight reliance on external funding. Free cash flow turned negative, suggesting cash management issues despite periods of positive operating cash flow in the past.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	39.12M	103.41M	7.47M	-1.59M	15.01M
Gross Profit	22.96M	100.18M	3.88M	-5.36M	4.58M
EBITDA	-15.89M	79.17M	-46.78M	-34.57M	-53.43M
Net Income	-41.97M	54.78M	-71.08M	-55.53M	-67.66M
Balance Sheet
Total Assets	152.49M	109.63M	63.73M	91.12M	88.69M
Cash, Cash Equivalents and Short-Term Investments	40.92M	30.37M	1.35M	21.21M	12.41M
Total Debt	40.62M	21.55M	44.44M	42.98M	71.17M
Total Liabilities	124.79M	49.69M	107.41M	89.79M	95.04M
Stockholders Equity	27.70M	59.94M	-43.69M	1.33M	-6.35M
Cash Flow
Free Cash Flow	-35.68M	23.53M	-33.80M	-37.37M	-43.54M
Operating Cash Flow	-35.53M	47.27M	-29.84M	-37.36M	-43.51M
Investing Cash Flow	-61.00K	-18.04M	-3.93M	69.00K	1.56M
Financing Cash Flow	46.08M	-171.00K	13.99M	46.02M	23.15M

Santhera Pharmaceuticals Holding Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SANN, the sentiment is Negative. The current price of 12.12 is below the 20-day moving average (MA) of 12.50, below the 50-day MA of 13.16, and below the 200-day MA of 12.29, indicating a bearish trend. The MACD of -0.34 indicates Negative momentum. The RSI at 41.15 is Neutral, neither overbought nor oversold. The STOCH value of 44.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SANN.

Santhera Pharmaceuticals Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NWRN	60 Neutral	CHF136.53M	9.69		―	450.19%	―
IDIA	53 Neutral	CHF441.51M	―		―	11.61%	-356.20%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.34%	16.99%	1.69%
RLF	50 Neutral	$27.04M	―	-38.10%	―	39.52%	83.79%
MOLN	47 Neutral	$124.96M	―	-40.40%	―	-66.82%	4.14%
SANN	39 Underperform	CHF154.00M	2.58	-93.91%	―	-62.17%	-166.33%